|
Jun 14
|
Eli Lilly unveils new manufacturing plant for GLP-1 pens
|
|
Jun 14
|
June consumer sentiment disappoints, Tesla short-selling: Catalysts
|
|
Jun 14
|
Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research
|
|
Jun 14
|
Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market
|
|
Jun 14
|
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
|
|
Jun 14
|
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
|
|
Jun 14
|
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
|
|
Jun 14
|
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
|
|
Jun 14
|
Zacks Market Edge Highlights: CAVA, Abercrombie & Fitch, Eli Lilly, CrowdStrike and Deckers Outdoor
|
|
Jun 14
|
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
|
|
Jun 13
|
5 Hot Growth Stocks: Buy on the Highs or Wait for a Pullback?
|
|
Jun 13
|
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
|
Jun 13
|
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term
|
|
Jun 13
|
Billionaire Israel Englander is Buying This Weight Loss Stock in 2024
|
|
Jun 13
|
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
|
|
Jun 13
|
Want to Get Richer? 2 Top Stocks to Buy Now and Hold Forever.
|
|
Jun 12
|
Market Chatter: Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan
|
|
Jun 12
|
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
|
|
May 14
|
2 Top Pharma Stocks That Just Keep Getting Better and Better
|
|
May 14
|
Is Eli Lilly's Latest Deal a Gamechanger?
|